tbuckley/cabot-search huggingface dataset:
P1-11 Four cases of definitive chemoradiotherapy with docetaxel/cisplatin/fluorouracil for advanced cervical esophageal cancer
Authors: Akinori Watanabe, Chikatoshi Katada, Yasuaki Furue, Takuya Wada, Kenji Ishido, Satoshi Tanabe, Wasaburo Koizumi
Journal: Annals of Oncology (2021)
P-53 Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis
Authors: R. Broadbent, R. Wheatley, S. Stajer, T. Jacobs, A. Lamarca, R. Hubner, J. Valle, E. Amir, M. McNamara
Journal: Annals of Oncology (2021)
Percutaneous Coronary Revascularization
Authors: Patrick W Serruys, Masafumi Ono, Scot Garg, Hironori Hara, Hideyuki Kawashima, Giulio Pompilio, Daniele Andreini, David R Holmes, Yoshinobu Onuma, Spencer B King Iii
Journal: Journal of the American College of Cardiology (2021)
Preparing for the NASH epidemic: A call to action
Authors: Fasiha Kanwal, Jay H. Shubrook, Zobair Younossi, Yamini Natarajan, Elisabetta Bugianesi, Mary E. Rinella, Stephen A. Harrison, Christos Mantzoros, Kim Pfotenhauer, Samuel Klein, Robert H. Eckel, Davida Kruger, Hashem El-Serag, Kenneth Cusi
Journal: Metabolism (2021)
Mineralocorticoid Receptor Antagonist Improves Cardiac Structure in Type 2 Diabetes
Authors: Niels H Brandt-Jacobsen, Per Lav Madsen, Marie Louise Johansen, Jon J Rasmussen, Julie L Forman, Maria R Holm, Niklas Rye Jørgensen, Jens Faber, Patrick Rossignol, Morten Schou, Caroline Kistorp
Journal: JACC Heart Failure (2021)
MO23-2 Significance of maintenance therapies in symptomatic multiple myeloma patients with HDT/ASCT
Authors: Aya Nakaya, Hirohiko Shibayama, Yuji Shimura, Satoru Kosugi, Hirokazu Tanaka, Shin-ichi Fuchida, Junya Kanda, Nobuhiko Uoshima, Hitomi Kaneko, Kazunori Imada, Kensuke Ohta, Tomoki Ito, Hideo Yagi, Satoshi Yoshihara, Masayuki Hino, Chihiro Shimazaki, Akifumi Takaori-Kondo, Junya Kuroda, Itaru Matsumura, Yuzuru Kanakura, Shosaku Nomura
Journal: Annals of Oncology (2021)
Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahepatic cholangiocarcinoma
Authors: Guido Carpino, Vincenzo Cardinale, Alessandra Di Giamberardino, Diletta Overi, Samantha Donsante, Tania Colasanti, Gaia Amato, Gianluca Mennini, Matteo Franchitto, Fabrizio Conti, Massimo Rossi, Mara Riminucci, Eugenio Gaudio, Domenico Alvaro, Carmine Mancone
Journal: Journal of Hepatology (2021)
3D bioprinting in cardiac tissue engineering
Authors: Zihan Wang, Ling Wang, Ting Li, Sitian Liu, Baolin Guo, Wenhua Huang, Yaobin Wu
Journal: Theranostics (2021)

Heart disease is the main cause of death worldwide. Because death of the myocardium is irreversible, it remains a significant clinical challenge to rescue myocardial deficiency. Cardiac tissue engineering (CTE) is a promising strategy for repairing heart defects and offers platforms for studying cardiac tissue. Numerous achievements have been made in CTE in the past decades based on various advanced engineering approaches. 3D bioprinting has attracted much attention due to its ability to integrate multiple cells within printed scaffolds with complex 3D structures, and many advancements in bioprinted CTE have been reported recently. Herein, we review the recent progress in 3D bioprinting for CTE. After a brief overview of CTE with conventional methods, the current 3D printing strategies are discussed. Bioink formulations based on various biomaterials are introduced, and strategies utilizing composite bioinks are further discussed. Moreover, several applications including heart patches, tissue-engineered cardiac muscle, and other bionic structures created via 3D bioprinting are summarized. Finally, we discuss several crucial challenges and present our perspective on 3D bioprinting techniques in the field of CTE.
Nine Lessons Learned From the COVID-19 Pandemic for Improving Hospital Care and Health Care Delivery
Authors: Eric K. Wei, Theodore Long, Mitchell H. Katz
Journal: JAMA Internal Medicine (2021)

New York City (NYC) was the epicenter of the COVID-19 pandemic in the US in March 2020.A dense city of only 302 square miles, it has had 33 359 deaths and 109 192 hospitalizations due to COVID-19 as of June 15, 2021. 1 In guiding NYC Health + Hospitals, the largest municipal hospital system in the US, through the pandemic, we have learned a number of lessons.Although there is much to debate about the national public health response to COVID-19, 2 we focus on the lessons learned through COVID-19 that we believe have applicability for improving hospital care in the future.The growth of telehealth has been covered elsewhere. 3,4We present 9 other lessons for improving hospital care and health care delivery.
Lolita Mei Wan Chan
Authors: Anthony Chan
Journal: BMJ (2021)

Lolita Mei Wan Chan was born in Leeds, the youngest and brightest of two siblings, to proud parents Chi Ming and Yuk Lin. She was among the first in our family to go to university and was a mathematician before studying medicine at St Andrews University and the University of Manchester. Lolita started as an academic foundation doctor and continued as academic clinical fellow in the north west of England. She undertook her medical training in gastroenterology before entering general practice. Lolita had a passion for medical education and was a visiting lecturer at the University …
Multidisciplinary Clinic Models: A Paradigm of Care for Management of NAFLD
Authors: Sonal Kumar, Rochelle Wong, Carolyn Newberry, Michele Yeung, Jessica M. Peña, Reem Z. Sharaiha
Journal: Hepatology (2021)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Recently Approved Alzheimer Drug Raises Questions That Might Never Be Answered
Authors: Rita Rubin
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
O7-4 Clinical utility of multi-disciplinary expert panel discussion in precision cancer medicine
Authors: Sadakatsu Ikeda, Ryo Kudo, Yamato Yamashita, Rika Noji, Jyunko Yokobori, Mika Ohki, Eriko Takamine, Yumi Kobayashi, Makiko Egawa, Yusuke Ebana, Koichiro Kimura, Kohta Yokoyama, Iichiro Onishi, Akira Takemoto, Susumu Kirimura, Yuko Kinowaki, Kosuke Tanimoto, Fuyuki Miya, Yoshihito Kano, Masayuki Yoshida, Satoshi Miyake
Journal: Annals of Oncology (2021)
New Software Can Aid in Early Autism Spectrum Disorder Diagnosis
Authors: Bridget M. Kuehn
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Human colon cancer cells G1 arrest in response to low doses of the dietary phytochemical chlorophyllin
Authors: Dario Diaz, Orianna Carter
Journal: Cancer Research (2004)

807  Colorectal tumorigenesis proceeds through an accumulation of genetic alterations in oncogenes and tumor suppressor genes. However, diet also plays a pivotal role in the temporal progression of normal colonic mucosa to adenoma and adencarcinoma stages. Studies on the mechanisms by which genetic and environmental factors affect malignant transformation have focused on deregulation of the homeostatic balance between cell proliferation and apoptosis in the colon. We have recently shown that sodium-copper chlorophyllin (CHL), a water-soluble salt of chlorophyll, markedly induces apoptosis in human colorectal cancer cells. The mechanism involved caspase8/caspase 6 and truncated Bid, with cleavage of nuclear lamins (Diaz et al Cancer Res 63, 1254-1261, 2003). Interestingly, at lower doses of CHL, which do not induce cell detachment and apoptosis, there was an apparent cell cycle arrest in HCT116 cells. FACS analyses showed this to involve the S phase of the cell cycle, and Western blotting implicated several key regulators of the cell cycle, or “checkpoint controls”, as being involved. Thus, whereas CHL had no effect on cyclins E and A or their associated cyclin-dependent kinases (CDKs), decreased expression was observed for cyclins D and B (and their associated CDK’s) as well as Rb and p21WAF1. Interestingly, very low concentrations of CHL (1-10 micromolar) induced an arrest in the G1-phase of the cell cycle, rather than in the S-phase. The mechanistic basis for this divergence at high and low doses of CHL is under investigation. However, it could provide insight into the unusual finding that CHL acts as a suppressing agent in the DMH-rat colon tumorigenesis model at high concentrations, but promotes tumorigenesis in the colon at low doses, accompanied by a shift in the spectrum of beta-catenin mutations (Blum et al Carcinogenesis 22, 315-320, 2001; Blum et al Mol Carcinogen 26, 195-203, 2003). This work was supported in part by NIH grants CA65525, CA80176, CA90890.
MO5-6 Prognostic factor in gastric cancer patients with patients who received nivolumab
Authors: Toshihiko Matsumoto, Tatsuki Ikoma, Kou Miura, Hiroki Nagai, Takao Tsuzuki, Shinjiro Takagi, Masahiro Takatani, Hisateru Yasui
Journal: Annals of Oncology (2021)
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to <i>Plasmodium falciparum</i> parasite resistance
Authors: James M. Murithi, Cécile Pascal, Jade Bath, Xavier Boulenc, Nina F. Gnädig, Charisse Flerida A. Pasaje, Kelly Rubiano, Tomas Yeo, Sachel Mok, Sylvie Klieber, Paul Desert, María Belén Jiménez-Díaz, Jutta Marfurt, Mélanie Rouillier, Mohammed H. Cherkaoui-Rbati, Nathalie Gobeau, Sergio Wittlin, Anne-Catrin Uhlemann, Ric N. Price, Grennady Wirjanata, Rintis Noviyanti, Patrick Tumwebaze, Roland A. Cooper, Philip J. Rosenthal, Laura M. Sanz, Francisco Javier Gamo, Jayan Joseph, Shivendra Singh, Sridevi Bashyam, Jean Michel Augereau, Elie Giraud, Tanguy Bozec, Thierry Vermat, Gilles Tuffal, Jean-Michel Guillon, Jérôme Menegotto, Laurent Sallé, Guillaume Louit, Marie-José Cabanis, Marie Françoise Nicolas, Michel Doubovetzky, Rita Merino, Nadir Bessila, Iñigo Angulo-Barturen, Delphine Baud, Lidiya Bebrevska, Fanny Escudié, Jacquin C. Niles, Benjamin Blasco, Simon Campbell, Gilles Courtemanche, Laurent Fraisse, Alain Pellet, David A. Fidock, Didier Leroy
Journal: Science Translational Medicine (2021)

The emergence and spread of Plasmodium falciparum resistance to first-line antimalarials creates an imperative to identify and develop potent preclinical candidates with distinct modes of action. Here, we report the identification of MMV688533, an acylguanidine that was developed following a whole-cell screen with compounds known to hit high-value targets in human cells. MMV688533 displays fast parasite clearance in vitro and is not cross-resistant with known antimalarials. In a P. falciparum NSG mouse model, MMV688533 displays a long-lasting pharmacokinetic profile and excellent safety. Selection studies reveal a low propensity for resistance, with modest loss of potency mediated by point mutations in PfACG1 and PfEHD. These proteins are implicated in intracellular trafficking, lipid utilization, and endocytosis, suggesting interference with these pathways as a potential mode of action. This preclinical candidate may offer the potential for a single low-dose cure for malaria.
Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis
Authors: Maria Laura Acosta Felquer, Luciano LoGiudice, Maria Laura Galimberti, Javier Rosa, Luis Mazzuoccolo, Enrique R Soriano
Journal: Annals of the Rheumatic Diseases (2021)

To compare the incidence of psoriatic arthritis (PsA) in patients with psoriasis (PsO) according to different treatments for their skin: topics/no treatment, conventional disease-modifying antirheumatic drugs (DMARDs) (cDMARDs) or biological DMARDs (bDMARDs).Patients with PsO without PsA followed at a university hospital were included in this retrospective cohort study. Patients were classified according to their treatment in topics (topics, phototherapy or no treatment), cDMARDs (methotrexate and cyclosporine) and bDMARDs (tumour necrosis factor inhibitors (TNFi), interleukin 17 inhibitors (IL-17i) and IL-12-23i ((interleukin (IL) 12/IL-23 inhibitor))) groups. Incident cases of PsA were attributed to one treatment if developed during the administration of that treatment. A Cox proportional hazards model was used to evaluate the adjusted risk of PsA development by treatment group.1719 patients with PsO contributed a total of 14 721 patient/years (py). 1387 (81%) patients were in the topics, 229 (13%) in cDMARDs and 103 (6%) in the bDMARDs group. During follow-up, 239 patients (14%) developed PsA (231 under topics, six under cDMARDs and two under bDMARDs). Global incidence was 1.6 per 100 py. The risk of developing PsA in patients with PsO treated with bDMARDs was significantly lower (incidence rate ratio (IRR)=0.26; 95% CI 0.03 to 0.94; p=0.0111), compared with topics, but not compared with cDMARDs (IRR=0.35; 95% CI 0.035 to 1.96; p=0.1007). Adjusted Cox proportional hazards regression analysis showed that male sex, nail involvement and higher body max index were associated with increased risk of developing PsA, while biologics use was protective (HR: 0.19; 95% CI 0.05 to 0.81).Treatment with biologics in patients with PsO reduced the risk of PsA development.
A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials
Authors: Nicole Fett, Victoria P. Werth
Journal: JAMA Dermatology (2021)

What are the roles of antimalarial therapy prescribers and eye care specialists in regard to antimalarial dosing, screening for retinal toxic effects, and antimalarial treatment cessation?Antimalarial prescribers should prescribe antimalarial dosages at 5 mg/kg/d or less of actual body weight. A baseline retinal examination with optical coherence tomography should be performed within 6 months of starting antimalarial therapy to rule out confounding disease. Patients at low risk for retinopathy do not require annual screening until 5 years of antimalarial use. Eye care clinicians should not stop treatment with antimalarials because of equivocal findings, as retinopathy occurs slowly, and therefore there is time for repeated testing. Antimalarial treatment cessation should be a collaborative decision that involves the patient, the prescriber, and the eye care clinician and that focuses on patient values, the severity of the underlying disease, and the estimated risk of visual loss if treatment with the drug is continued.
Comparative Analysis of Mammal Genomes Unveils Key Genomic Variability for Human Life Span
Authors: Xavier Farré, Ruben Molina, Fabio Barteri, Paul R H J Timmers, Peter K Joshi, Baldomero Oliva, Sandra Acosta, Borja Esteve-Altava, Arcadi Navarro, Gerard Muntané
Journal: Molecular Biology and Evolution (2021)

The enormous mammal's lifespan variation is the result of each species' adaptations to their own biological trade-offs and ecological conditions. Comparative genomics have demonstrated that genomic factors underlying both, species lifespans and longevity of individuals, are in part shared across the tree of life. Here, we compared protein-coding regions across the mammalian phylogeny to detect individual amino acid (AA) changes shared by the most long-lived mammals and genes whose rates of protein evolution correlate with longevity. We discovered a total of 2,737 AA in 2,004 genes that distinguish long- and short-lived mammals, significantly more than expected by chance (P = 0.003). These genes belong to pathways involved in regulating lifespan, such as inflammatory response and hemostasis. Among them, a total 1,157 AA showed a significant association with maximum lifespan in a phylogenetic test. Interestingly, most of the detected AA positions do not vary in extant human populations (81.2%) or have allele frequencies below 1% (99.78%). Consequently, almost none of these putatively important variants could have been detected by genome-wide association studies. Additionally, we identified four more genes whose rate of protein evolution correlated with longevity in mammals. Crucially, SNPs located in the detected genes explain a larger fraction of human lifespan heritability than expected, successfully demonstrating for the first time that comparative genomics can be used to enhance interpretation of human genome-wide association studies. Finally, we show that the human longevity-associated proteins are significantly more stable than the orthologous proteins from short-lived mammals, strongly suggesting that general protein stability is linked to increased lifespan.
MO11-7 The decision of adjuvant treatment using OncotypeDX and outcome in early breast cancer patients
Authors: Yuri Ozaki, Masataka Sawaki, Masaya Hattori, Akiyo Yoshimura, Haruru Kotani, Yayoi Adachi, Ayumi Kataoka, Kayoko Sugino, Nanae Horisawa, Yuka Endo, Kazuki Nozawa, Shoko Sakamoto, Daiki Takatsuka, Hiroji Iwata
Journal: Annals of Oncology (2021)
Genomic Evidence for Speciation with Gene Flow in Broadcast Spawning Marine Invertebrates
Authors: Shotaro Hirase, Yo Y Yamasaki, Masashi Sekino, Masato Nishisako, Minoru Ikeda, Motoyuki Hara, Juha Merilä, Kiyoshi Kikuchi
Journal: Molecular Biology and Evolution (2021)

How early stages of speciation in free-spawning marine invertebrates proceed is poorly understood. The Western Pacific abalones, Haliotis discus, H. madaka, and H. gigantea, occur in sympatry with shared breeding season and are capable of producing viable F1 hybrids in spite of being ecologically differentiated. Population genomic analyses revealed that although the three species are genetically distinct, there is evidence for historical and ongoing gene flow among these species. Evidence from demographic modeling suggests that reproductive isolation among the three species started to build in allopatry and has proceeded with gene flow, possibly driven by ecological selection. We identified 27 differentiation islands between the closely related H. discus and H. madaka characterized by high FST and dA, but not high dXY values, as well as high genetic diversity in one H. madaka population. These genomic signatures suggest differentiation driven by recent ecological divergent selection in presence of gene flow outside of the genomic islands of differentiation. The differentiation islands showed low polymorphism in H. gigantea, and both high FST, dXY, and dA values between H. discus and H. gigantea, as well as between H. madaka and H. gigantea. Collectively, the Western Pacific abalones appear to occupy the early stages speciation continuum, and the differentiation islands associated with ecological divergence among the abalones do not appear to have acted as barrier loci to gene flow in the younger divergences but appear to do so in older divergences.
Aldo-Keto Reductases and Cancer Drug Resistance
Authors: Trevor M. Penning, Sravan Jonnalagadda, Paul C. Trippier, Tea Lanišnik Rižner
Journal: Pharmacological Reviews (2021)

Human aldo-keto reductases (AKRs) catalyze the NADPH-dependent reduction of carbonyl groups to alcohols for conjugation reactions to proceed. They are implicated in resistance to cancer chemotherapeutic agents either because they are directly involved in their metabolism or help eradicate the cellular stress created by these agents (e.g., reactive oxygen species and lipid peroxides). Furthermore, this cellular stress activates the Nuclear factor-erythroid 2 p45-related factor 2 (NRF2)-Kelch-like ECH-associated protein 1 pathway. As many human <i>AKR</i> genes are upregulated by the NRF2 transcription factor, this leads to a feed-forward mechanism to enhance drug resistance. Resistance to major classes of chemotherapeutic agents (anthracyclines, mitomycin, <i>cis-</i>platin, antitubulin agents, vinca alkaloids, and cyclophosphamide) occurs by this mechanism. Human AKRs also catalyze the synthesis of androgens and estrogens and the elimination of progestogens and are involved in hormonal-dependent malignancies. They are upregulated by antihormonal therapy providing a second mechanism for cancer drug resistance. Inhibitors of the NRF2 system or pan-AKR1C inhibitors offer promise to surmount cancer drug resistance and/or synergize the effects of existing drugs. <h3>Significance Statement</h3> Aldo-keto reductases (AKRs) are overexpressed in a large number of human tumors and mediate resistance to cancer chemotherapeutics and antihormonal therapies. Existing drugs and new agents in development may surmount this resistance by acting as specific AKR isoforms or AKR pan-inhibitors to improve clinical outcome.
PD3-1-5 Evaluation of inter-assay variability of next-generation sequencing based gene panels
Authors: Quy Pham Nguyen, Masashi Kanai, Keita Fukuyama, Tadayuki Kou, Tomohiro Kondo, Masahiro Yoshioka, Junichi Matsubara, Sachiko Minamiguchi, Shigemi Matsumoto, Manabu Muto
Journal: Annals of Oncology (2021)